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Abstract  11 
The ability of Epstein-Barr virus (EBV) to spread and persist in human populations relies 12 
on a balance between host immune responses and EBV immune-evasion. CD8+ cells 13 
specific for EBV late lytic cycle antigens show poor recognition of target cells compared 14 
to immediate early and early antigen-specific CD8+ cells. This phenomenon is in part 15 
due to the early EBV protein, BILF1, whose immunosuppressive activity increases with 16 
lytic cycle progression. However, published data suggest the existence of a hitherto 17 
unidentified immune-evasion protein further enhancing protection against late EBV 18 
antigen-specific CD8+ cells. We have now identified the late lytic gene, BDLF3, as the 19 
missing link accounting for the efficient evasion during late lytic cycle. Interestingly, 20 
BDLF3 also contributes to evasion of CD4+ cell responses to EBV.  We report that 21 
BDLF3 down-regulates expression of surface MHC class I and class II molecules in the 22 
absence of any effect upon other surface molecules screened, including CD54 (ICAM-1) 23 
and CD71 (Transferrin receptor). BDLF3 both enhanced internalization of surface MHC 24 
molecules and reduced the rate of their appearance at the cell surface. The reduced 25 
expression of surface MHC molecules correlated with functional protection against 26 
CD8+ and CD4+ T cell recognition. The molecular mechanism was identified as BDLF3-27 
induced ubiquitination of MHC molecules and their subsequent downregulation in a 28 
proteasomal dependent manner.  29 
 30 
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Importance 31 
Immune-evasion is a necessary feature of viruses that establish life-long persistent 32 
infections in the face of strong immune-responses. EBV is an important human 33 
pathogen whose immune evasion mechanisms are only partly understood. Of the EBV 34 
immune-evasion mechanisms identified to date, none could explain why CD8+ T cell 35 
responses to late lytic cycle genes are so infrequent and, when present, recognize 36 
lytically-infected target cells so poorly relative to CD8+ T cells specific for early lytic 37 
cycle antigens. The present work identifies an additional immune-evasion protein, 38 
BDLF3 that is expressed late in lytic cycle and impairs CD8+ T cell recognition by 39 
targeting cell surface MHC class I molecules for ubiquitination and proteasomal 40 
dependent downregulation. Interestingly, BDLF3 also targets MHC class II molecules, to 41 
impair CD4+ T cell recognition. BDLF3 is therefore a rare example of a viral gene that 42 
impairs both the class I and class II MHC antigen presenting pathways. 43 
44 
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Introduction 45 
Epstein-Barr virus (EBV) is a γ-herpesvirus found in more than 90% of the human 46 
population. Primary infection with EBV is usually followed by establishment of lifelong 47 
latent infection with occasional reactivation (1). The balance between host immune 48 
responses, including CD4+ and CD8+ T cells, and viral immune evasion of these 49 
responses is key to the spread and survival of EBV in human populations. Passive 50 
evasion through the ability to establish antigenically silent latent infections is an 51 
important characteristic of all herpesviruses, including EBV. In addition, active evasion 52 
mechanisms are an important feature of herpesviruses. As these active evasion 53 
mechanisms are predominantly observed during the lytic phase of the herpesvirus life-54 
cycle, they are presumed to be particularly important for enabling virus spread. There 55 
have been a number of EBV encoded immune evasion genes identified that are 56 
expressed in lytic cycle and target the MHC class I or class II antigen presentation 57 
pathways (2, 3). Those genes responsible for interfering with MHC class I antigen 58 
presentation include BGLF5, BNLF2a and BILF1 which each act upon different 59 
elements of the MHC class I antigen presentation pathway (3-7). The EBV encoded 60 
proteins BGLF5, BZLF1 and gp42 have been shown to interfere with MHC class II 61 
antigen presentation (5, 8-10). 62 
The above-mentioned MHC class I evasion genes encoded by EBV have been well 63 
studied and shown to act via different mechanisms upon different elements of the MHC 64 
class I antigen presentation pathway. Briefly, BGLF5 is a host shut off protein that has 65 
been shown to induce the degradation of MHC class I mRNA, thereby reducing cell 66 
5 
 
surface MHC class I peptide presentation (5, 11). BILF1 is known to target both cell 67 
surface MHC class I molecules and those on route to the surface for degradation thus 68 
reducing the presentation of peptides to CD8+ T cells (7, 12, 13). Finally, BNLF2a 69 
inhibits the function of the transporter associated with antigen processing (TAP), which 70 
reduces the supply of peptides for loading on to MHC class I molecules, thus reducing 71 
the level of MHC class I:peptide presentation to CD8+ T cells (4, 14, 15).  72 
Our group recently investigated the relevance of BGLF5, BNLF2a and BILF1 immune 73 
evasion genes in the context of lytic virus infection (16). It was concluded that BGLF5 in 74 
fact plays a minimal role in protecting EBV infected cells against T cell recognition, and 75 
that BNLF2a plays an important role of protecting cells during the immediate early and 76 
early stages of lytic cycle, contributing little protection at late stage lytic cycle (IE>E>>L) 77 
(14, 16). BILF1 was shown to contribute minimal protection during immediate early 78 
stage lytic cycle, a reasonable level of protection during early stage lytic cycle and a 79 
more dramatic level of protection was observed during late stage lytic cycle (IE<E<<L) 80 
(16). This investigation revealed a level of co-operation between EBV encoded MHC 81 
class I immune evasion genes in order to protect cells from CD8+ T cell recognition. 82 
However, CD8+ T cell responses to late lytic cycle antigens still recognize lytically-83 
infected target cells relatively poorly, even in the absence of BILF1 expression. (16, 17). 84 
This implies that another as yet unidentified immune evasion gene or genes may be 85 
functioning late in lytic cycle. 86 
In comparison to what is known about the immune evasion of MHC class I antigen 87 
presentation, the evasion of MHC class II antigen presentation by EBV is less well 88 
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understood. Over-expression of the host shut off protein, BGLF5 has been shown to 89 
result in a reduced level of surface MHC class II (5). In addition, the immediate early 90 
protein BZLF1 has been shown to interfere with MHC class II antigen presentation by 91 
modulating the expression of cell surface invariant chains (8). A third EBV encoded 92 
gene, BZLF2 (gp42), has been shown to interfere with MHC class II antigen 93 
presentation to CD4+ T cells by sterically hindering MHC class II interaction with the T 94 
cell receptor, thus blocking CD4+ T cell recognition (9, 10). To date, no other EBV 95 
proteins have been identified as potential CD4+ T cell immune evasion proteins.  96 
The present study sought to identify novel candidate EBV genes responsible for 97 
interfering with MHC class I antigen presentation during late phase lytic cycle, and thus 98 
providing an explanation for the pronounced immune evasion observed at that stage in 99 
the lytic cycle. Screening experiments revealed that the late lytic protein, BDLF3, whose 100 
functions are unknown (18-20), was able to impair MHC class I antigen presentation. 101 
Unexpectedly, BDLF3 also impaired CD4+ T cell recognition of MHC class II presented 102 
peptides. The molecular mechanism for the effect of BDLF3 on antigen presentation 103 
involved ubiquitination and proteasomal dependent downregulation of surface MHC 104 
class I and class II molecules.    105 
106 
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Materials and methods 107 
 108 
Plasmids 109 
The previously described (7) expression plasmid pCDNA3-IRES-GFP, a kind gift from 110 
Professor Emmanuel Wiertz (Utrecht Medical Center, Netherlands), was used to 111 
subclone and express a selection of EBV genes. The p509 expression plasmid for 112 
BZLF1, a kind gift from Professor Paul Farrell (Imperial College London, UK), has also 113 
been described (11) as has the cytoplasmic EBNA1 expression vector (21). The 114 
retroviral plasmid PLZRS-NGFR, also a kind gift from Professor Emmanuel Wiertz, was 115 
used to subclone PLZRS-BDLF3-NGFR and both were used in transient transfections to 116 
allow for in house sorting of transfected cells, on the expression of surface truncated 117 
nerve growth factor receptor (NGFR). 118 
 119 
Cells, transfections and electroporations   120 
The MJS (Mel JuSol) melanoma-derived cell line (22), and the EBV negative Burkitt 121 
lymphoma cell line DG75 (23) were maintained in RPMI 1640 supplemented with 10% 122 
fetal calf serum (FCS). CIITA-293 cells are HEK-293 cells stably expressing CIITA (24) 123 
and were a kind gift from Dr Andrew Hislop, University of Birmingham. These were 124 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 125 
FCS. The myelogenous leukemia cell line K562, transduced to express either HLA-A2, -126 
B35, -Cw1, -DR or –DQ (a kind gift from Professor Emmanuel Wiertz, Utrecht) were 127 
maintained in RPMI 1640 supplemented with 10% FCS plus 400µg/ml of geneticin 128 
(Invitrogen). EBV specific CD4+ and CD8+ T cell clones were grown in RPMI 1640 129 
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supplemented with 10% FCS, 5% human serum, 30% supernatant from the interleukin-130 
2 producing MLA 144 cell line (25) and 50 U/ml recombinant interleukin-2, as described 131 
previously (17). 132 
Transient transfection of MJS and 293-CIITA cells with plasmid DNA was performed 133 
using lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. 134 
Transient expression of plasmid DNA using DG75 cells and K562 cells was performed 135 
by electroporating cells at 290V and 950µF in 4mm gap cuvettes. In some experiments, 136 
cells transiently transfected with NGFR expressing plasmids were positively selected for 137 
the surface expression of NGFR using MACSelect NGFR-Transfected Cell Selection 138 
kits, as per manufacturer’s protocol (Miltenyi Biotec). 139 
 140 
Antibodies 141 
For immunoprecipitation experiments and for internalization/appearance assays, 142 
unconjugated W6/32 and L243 murine monoclonal antibodies (MAbs) to human MHC 143 
molecules were obtained from Biolegend: W6/32 (26) recognizes native β2 144 
microglobulin-associated MHC class I complexes (HLA-A, -B and –C alleles); and L243  145 
for HLA-DR. For flow cytometry experiments, APC- and PE- conjugated antibodies to 146 
HLA class I (W6/32), HLA-DR (L243), ICAM1/CD54 (HCD54) and transferrin 147 
receptor/CD71 (TfR, CY1G4) were purchased from Biolegend. For western blotting, 148 
mouse anti-ubiquitin antibody (P4D1) MAb was purchased from Biolegend. Goat 149 
antibodies to calregulin were purchased from Santa Cruz Biotechnology. The BZ.1 150 
murine MAb specific for the EBV BZLF1-encoded protein was generated by our 151 
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laboratory (27). The rabbit anti-BDLF3 (V8) serum was a kind gift from Dr. L.Hutt-152 
Fletcher (19). 153 
 154 
Flow cytometry analysis of cell surface MHC class I and class II molecules 155 
Cell surface expression of MHC class I and class II was determined by staining cells 156 
with APC- or PE- conjugated anti-HLA class I or class II antibodies and detected on 157 
BDbiosciences Accuri C6 Flow Cytometer. Data were analyzed using FlowJo software 158 
(TreeStar). 159 
The kinetics of internalization and appearance of cell surface MHC molecules were 160 
determined essentially as described previously (12).To assay the kinetics of surface 161 
MHC class I and class II internalization, MJS cells were incubated on ice with saturating 162 
amounts of anti-MHC class I (W6/32) or anti-MHC class II (L243) MAbs. Cells were then 163 
washed three times in phosphate-buffered normal saline (PBS) and placed in culture 164 
medium at 37ºC for 60 mins. Aliquots of cells were taken at those times shown in 165 
results, and were rapidly cooled to 0ºC to inhibit further membrane trafficking. The level 166 
of W6/32 or L243 MAb remaining at the cell surface was then analyzed by staining cells 167 
with APC-conjugated goat anti-mouse IgG2a antibody (Biolegend). Cells were analyzed 168 
using flow cytometry.   169 
To assay the kinetics of MHC class I and II appearance, MJS cells were again 170 
incubated with saturating amounts of W6/32 or L243 for 60 mins on ice. Cells were 171 
washed three times in PBS and then placed in warm culture medium at 37ºC for 60min, 172 
cells were analyzed at times indicated in results. After cooling to 0ºC, to prevent further 173 
appearance of molecules at the surface through membrane trafficking, cells were 174 
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stained with APC-conjugated W6/32 or APC-conjugated L243 and analyzed using flow 175 
cytometry. These directly conjugated anti-MHC detection antibodies will only bind to 176 
MHC molecules that have appeared since the excess unconjugated blocking antibody 177 
was washed away immediately prior to beginning the incubations in warmed medium. 178 
Note that the MHC molecules newly-arrived at the cell surface are likely to be a mixture 179 
of de-novo synthesized molecules arriving at the surface for the first time, and recycled 180 
molecules that had previously been endocytosed. 181 
 182 
Flow cytometric analysis of whole cell (intracellular) proteins 183 
Intracellular staining for HLA class I and class II was performed to quantify the total 184 
cellular levels of these proteins. Washed pellets of 0.5x106 cells were first fixed using 185 
100µl Ebiosciences intracellular (IC) fixative for 1h on ice, followed by permeabilization 186 
using 100µl (0.2%) Triton X-100 and further 30 min incubation on ice. After washing in 187 
PBS, cells were incubated with appropriate conjugated antibody for 1h at 37ºC. Cells 188 
were then washed in PBS and analyzed using flow cytometry.  189 
 190 
T cell function assays 191 
‘RAK’ CD8+ T cell clones specific for the RAKFKQLL peptide originating from BZLF1 192 
protein, and ‘SNP’ CD4+ clones specific for the SNPKFENIAEGLRVLLARSH epitope 193 
from ENBA1 protein, were generated as previously described (16). Targets for RAK-194 
specific CD8+ T cells were generated by co-transfection of MJS cells with BZLF1 and 195 
control-GFP or BDLF3-GFP expression plasmids. At 24h post transfection, cells were 196 
used as targets for RAK specific CD8+ T cell clones. T cell recognition was determined 197 
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by interferon gamma (IFN-γ) enzyme-linked immunosorbant assay (ELISA) using a 198 
previously described protocol (16). Targets for SNP-specific CD4+ T cell clones were 199 
generated by transfection of MJS cells with the cytoplasmic EBNA1 expression plasmid, 200 
EBNA1ΔNLS, which generates a target protein that is efficiently processed via the MHC 201 
antigen presentation pathway (21). At 24h post-transfection cells were re-seeded and 202 
24h later these cells were transfected with control-NGFR or BDLF3-NGFR expression 203 
plasmids. After a further 24h, cells were harvested and sorted as described above and 204 
the recognition of these target cells by SNP-specific CD4+ T cell clones was determined 205 
by IFN-γ ELISA. 206 
 207 
Immunoprecipitation 208 
Positively selected control-NGFR and BDLF3-NGFR expressing MJS cells (2x106) were 209 
used for surface MHC class I and class II immunoprecipitation. Cells were incubated for 210 
two hours on ice with anti-HLA class I Mab (W6/32) or anti-HLA class II Mab (L243), 211 
then washed and lysed using 400µl of NP-40 buffer (0.5% Nonidet P-40, 5mM MgCl2 212 
and 50mM Tris-HCl, pH7.5) with protease inhibitor cocktail (Sigma P8340) at 4ºC for 45 213 
min. Nuclei and insoluble debris were removed by centrifugation, and the supernatants 214 
were incubated with 20µl Dynabeads Protein A and 20µl Dynabeads Protein G 215 
(Invitrogen) at 4ºC overnight. Beads were then washed four times with NET buffer (0.5% 216 
NP-40, 150mM NaCl2, 5mM EDTA and 50mM Tris-HCl, pH 7.5) and the precipitated 217 
proteins were eluted by boiling in reducing sample buffer for 5 min. Finally, samples 218 
were separated by SDS-PAGE on 4-12 % Bis-Tris NuPage mini-gels with 219 
morpholinepropanesulfonic acid (MOPS) electrolysis buffer (Invitrogen). 220 
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Western blotting 221 
Total cell lysates were denatured in reducing sample buffer and then sonicated and 222 
heated to 100ºC for 5 min. Solubilized proteins equivalent to 2x105 cells/20µl sample 223 
were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on to 4-12% 224 
acrylamide gradient bis-Tris NuPage minigels with MOPS running buffer (Invitrogen). 225 
226 
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Results 227 
The late lytic gene BDLF3 is identified as an immune evasion protein  228 
As previously demonstrated, EBV encodes a number of immune evasion genes that co-229 
operate to afford the protection of EBV infected cells against recognition by CD8+ T cells 230 
during lytic cycle. However, it has been hypothesized that an as yet unidentified EBV 231 
lytic gene may be responsible for the ultimate protection of EBV infected cells during 232 
late lytic cycle (16). In order to identify other potential EBV immune evasion proteins 233 
involved in protecting infected cells against CD8+ T cell recognition, more than 25 EBV 234 
genes expressed during lytic cycle were transiently expressed in MJS cells using 235 
bicistronic plasmid vectors that co-expressed GFP with the test gene (Supplementary 236 
Fig. 1A). The expression of GFP protein allowed for the identification of transfected cells 237 
using flow cytometry. At 24h post-transfection, flow cytometric analysis was used to 238 
analyse surface expression levels of MHC class I on GFP positive cells. Of all EBV lytic 239 
genes included in this screen the only protein that reproducibly affected surface levels 240 
of MHC class I was BDLF3 (Fig. 1A). Fig. 1A shows a representative selection of these 241 
screens. As a control, the level of surface MHC class II was also analyzed in this screen 242 
(Supplementary Fig. 1B). Interestingly, BDLF3 also affected the surface expression of 243 
MHC class II (Fig. 1B).  244 
BDLF3 has previously been classified as a late expressed lytic protein (19). We 245 
confirmed the late expression kinetics using the EBV positive cell line, AKBM (9) that 246 
can be induced in to lytic cycle by cross linking of the B cell receptor. Following 247 
induction, aliquots of induced AKBM cells were taken at 0h, 1h, 6h, 12h, 24h, and 48h 248 
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time points and immunoblotting was performed in order to detect the expression of 249 
BDLF3 and the immediate early protein BZLF1. As shown in Fig. 1C, BDLF3 protein 250 
expression is detected weakly at 12hr post induction but with stronger expression seen 251 
at 24hr. These expression kinetics are consistent with previous findings (19) and 252 
suggests that BDLF3 could potentially be the ‘missing link’ immune evasion protein 253 
responsible for interfering with MHC class I antigen presentation during late stage lytic 254 
cycle to protect these cells against CD8+ T cell recognition. In addition, the effect on 255 
expression of MHC class II molecules raised the possibility that BDLF3 also plays a role 256 
in CD4+ T cell immune evasion. To confirm that the levels of BDLF3 protein expression 257 
in our transfected cells were physiologically relevant, BDLF3 protein expression levels 258 
in the transfected MJS cells was compared with BDLF3 expression level in induced 259 
AKBM cells after adjusting for the percentage of GFP+ cells in MJS cells and 260 
percentage of VCA+ cells in induced AKBM cells. Quantification of western blots 261 
(Supplementary Fig. 2) showed that the expression of BDLF3 in MJS was around 70% 262 
of that expressed in induced AKBM cells.   263 
In order to confirm that BDLF3 acts specifically on MHC class I and MHC class II, MJS 264 
cells transiently expressing BDLF3 were harvested at 24hr post-transfection and were 265 
analyzed in more detail using flow cytometry to detect surface levels of MHC class I, 266 
MHC class II, and other cell surface proteins. The results in Fig. 2A indicated that 267 
BDLF3 expressing cells (dashed line) exhibit a 60% decrease in surface MHC class I 268 
mean fluorescence intensity (MFI) compared to control cells (solid black line). A similar 269 
result was observed for surface levels of MHC class II on BDLF3 positive cells (Fig. 2B), 270 
where there was a reduction of 50% in MHC class II MFI. Importantly, the levels two 271 
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other surface proteins tested, Transferrin receptor (TfR; Fig. 2C) and ICAM1, (Fig. 2D) 272 
were not affected by the expression of BDLF3.  273 
Since B cells are the natural reservoir for EBV, we next investigated the phenotype of 274 
BDLF3 in B cells. To this end, the effect of transient BDLF3 expression on surface MHC 275 
molecules on the EBV negative B cell line, DG75 was investigated using flow cytometry. 276 
In this instance, the control of ICAM1 could not be included as its expression on DG75 277 
cells is negligible; therefore the effect of BDLF3 on expression of CD19 was analyzed 278 
along with TfR expression. As shown in Fig. 2E-H, results similar to those seen in MJS 279 
cells were obtained. BDLF3 expressing DG75 cells showed a 43% reduction in the MFI 280 
of MHC class I (Fig. 2E) and a 30% reduction in MHC class II (Fig. 2F) compared to 281 
control cells not expressing BDLF3. There was no observed effect of BDLF3 on the 282 
expression of surface TfR (Fig. 2G) or CD19 (Fig. 2H).  283 
 284 
BDLF3 induces downregulation of all screened MHC class I and MHC class II 285 
alleles 286 
Since some viral immune evasion genes, including BILF1, have been shown to 287 
preferentially target specific HLA class I alleles (13), we next sought to investigate the 288 
HLA-specificity of BDLF3. To do so, MHC class I negative K562 cells engineered to 289 
stably express HLA-A2, -B35 or –Cw1 were transiently transfected to express either 290 
BDLF3 or a control vector. At 24h post-transfection the surface level HLA-A2, -B35 and 291 
–Cw1 on positively transfected cells was detected using flow cytometry. As shown in 292 
Fig. 3A, cells expressing BDLF3 showed a decrease in the cell surface level of HLA-A2 293 
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(upper histograms) (27% reduction in MFI), HLA-B35 (middle histograms) (34% 294 
reduction in MFI) and HLA-Cw1 (lower histograms) (26% reduction in MFI) compared to 295 
control cells. A similar approach was then used to test the specificity of BDLF3 for HLA 296 
class II alleles. Here, HLA class II negative HEK-293 cells engineered to stably 297 
expressing CIITA, thus driving the surface expression of HLA-DR and -DQ, were 298 
transiently transfected to express BDLF3 or control vector. Similar to that seen for HLA 299 
class I alleles, BDLF3 induced a reduction in both HLA-DR (47% reduction in MFI) (Fig. 300 
3B, upper histograms) and HLA DQ (32% reduction in MFI) (Fig. 3B, lower histograms) 301 
compared to control transfected cells. In all examples the level of surface TfR remained 302 
similar between BDLF3 and control transfected cells (data not shown). These results 303 
indicate that BDLF3 is not selective in down-regulating HLA molecules but instead acts 304 
more broadly to down regulate all HLA class I and HLA class II molecules. 305 
 306 
BDLF3 mediated reductions in surface MHC class I and class II confers protection 307 
against both CD8+ and CD4+ T cell recognition 308 
Since BDLF3 induces a reduction in the level of surface MHC class I and class II 309 
molecules, we next investigated whether BDLF3 expression provided protection against 310 
recognition by EBV-specific CD8+ and CD4+ T cells. In order to address this, the HLA-311 
B8 positive cell line MJS cells, were co-transfected with BZLF1 and either BDLF3-GFP 312 
or control-GFP vector plasmids (Fig. 4A). At 24h post-transfection these cells were used 313 
as targets in a T cell assay with CD8+ T cell clones restricted through HLA-B8 and 314 
specific for the peptide RAKFKQLL, contained within the BZLF1 antigen. T cell 315 
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recognition was measured as IFN-γ release using IFN-γ ELISA. As shown in one 316 
representative experiment (n=3) in Fig. 4A, the expression of BDLF3 resulted in a 317 
significant decrease in IFN-γ release by RAK-specific T cell clones, from ~1100pg/ml to 318 
~500pg/ml. The BDLF3-mediated reduction in BZLF1-specific CD8+ T cell recognition 319 
was not due to any change in the expression of BZLF1 target protein expression (Fig. 320 
4B). 321 
In order to investigate the ability of BDLF3 to protect cells against recognition by CD4+ T 322 
cells, a similar method was employed. Here, MJS cells stably expressing the HLA class 323 
II allele DR51 were transfected to express cytoplasmic EBNA1 for 48h and either 324 
BDLF3-NGFR or control-NGFR vector for a further 24hr (Fig. 4C). Cells were then 325 
sorted on expression of NGFR and subsequently used as targets for a CD4+ T cell 326 
clones specific for the HLA-DR51 restricted epitope SNPKFENIAEGLRVLLARSH, 327 
contained within EBNA1. As shown in Fig. 4C, the expression of BDLF3 resulted in a 328 
decrease in T cell recognition (IFN-γ release) by SNP-specific CD4+ T cell clones from 329 
~1300pg/ml to ~900pg/ml, compared to control cells. The BDLF3-mediated reduction in 330 
EBNA1-specific CD4+ T cell recognition was not due to any change in the expression of 331 
EBNA1 target protein expression (Fig. 4D). Thus, in a similar pattern to those results 332 
seen for BDLF3 protection against CD8+ T cell recognition, BDLF3 induced reduction in 333 
surface MHC class II molecules also correlated with protection against CD4+ T cell 334 
recognition.  335 
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These data show that BDLF3 induced reduction in cell surface MHC class I and class II 336 
is functional in protecting BDLF3 expressing cells against recognition by both CD8+ and 337 
CD4+ T cells.  338 
BDLF3 downregulates surface MHC molecules more dramatically than total MHC 339 
molecules 340 
To explore the mechanism of MHC class I and class II downregulation by BDLF3, we 341 
first asked whether the total cellular pool of MHC molecules was affected, or whether 342 
surface MHC molecules were selectively targeted. To this end, flow cytometry of 343 
intracellular staining of fixed and permeabilized cells was used to detect the level of 344 
whole cell MHC molecules compared to surface MHC molecules detected on 345 
impermeable viable cells. As expected, surface level MFI of MHC class I and class II 346 
were both reduced by approximately 50% on cells expressing BDLF3 compared to 347 
control cells (Fig. 5A, left-hand column). This difference was found to be significant (Fig. 348 
5B, white bars). Interestingly, there was only a slight decrease of 10% in the MFI of 349 
whole cell MHC class I and MHC class II compared to control cells (Fig. 5A, right 350 
column) and this small reduction was not statistically significant when the results from 351 
three independent experiments were pooled and analyzed  (Fig. 5B, grey bars). To 352 
confirm these findings by an independent method, control GFP expressing MJS and 353 
BDLF3-GFP expressing MJS cells were purified using Mo-flow cell sorter and the 354 
expression of total MHC-I and MHC-II was examined by western-blot. The result 355 
showed no significant difference (supplementary Fig.3), confirming the result from 356 
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intracellular flow cytometry data. Importantly, BDLF3 had no effect on surface or whole 357 
cell levels of ICAM1 expression (Figs. 5A and 5B, bottom panel).  358 
These data show that BDLF3 affects the levels of surface MHC molecules more 359 
dramatically than it affects whole cell MHC molecules, suggesting that BDLF3 exerts its 360 
function predominantly on surface MHC class I and II rather than the intracellular 361 
fraction of these molecules.   362 
 363 
BDLF3 induces rapid internalization and delayed appearance of MHC molecules 364 
Since BDLF3 predominantly targets surface MHC molecules, we next examined 365 
whether it targets those MHC molecules already at the cell surface or those trafficking to 366 
the cell surface. We therefore compared the kinetics of MHC class I and class II 367 
internalization and appearance at the cell surface of BDLF3 expressing cells using flow 368 
cytometry. Representative examples are shown of MHC class I (Fig. 6A, upper) and 369 
class II (Fig. 6A, lower) internalization assays, where the percentage of MHC class I and 370 
class II remaining on the surface of BDLF3 expressing and control cells was measured 371 
over 60 minutes. Cells expressing BDLF3 showed lower levels of surface MHC 372 
remaining at the cell surface at each time point indicated, such that by 60min there were 373 
respectively 20% and 13% less surface MHC class I and MHC class II on BDLF3 374 
expressing cells compared to control cells. These data indicate that BDLF3 induces a 375 
more rapid rate of both MHC class I and MHC class II internalization.  376 
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When a similar assay was used to measure the rate of MHC class I and class II surface 377 
appearance, BDLF3 expressing cells conversely showed a decreased rate of both MHC 378 
class I and class II surface appearance at each time point compared to control cells 379 
(Fig. 6B). By 60 min, the appearance of MHC class I and class II on BDLF3 expressing 380 
cells at time point 60min was reduced by 50% and 47% respectively in comparison to 381 
control cells. This BDLF3-mediated reduction in the rate of appearance of MHC at the 382 
surface (Fig. 6B) was noticeably greater than the accelerated rate of endocytosis 383 
(Fig.6A). 384 
It should be noted that in all experiments rate of TfR internalization or appearance 385 
remained similar between control and BDLF3 expressing cells (data not shown). These 386 
data indicate that BDLF3 is able to both enhance endocytosis of MHC molecules at the 387 
cell surface and interfere with the trafficking of intracellular MHC molecules to the cell 388 
surface. 389 
 390 
BDLF3 downregulation of surface MHC molecules involves ubiquitination and the 391 
proteasomal pathway   392 
We next sought to identify the mechanism by which BDLF3 is able to enhance 393 
internalization and delay the appearance of surface MHC class I and MHC class II 394 
molecules. Our initial experiments were designed to identify which pathway BDLF3 395 
might utilize in order to reduce the expression of surface MHC molecules. To this end, 396 
we incubated BDLF3 expressing cells with proteasomal and lysosomal inhibitors. In the 397 
absence of drug treatment, cells expressing BDLF3 showed lower levels of surface 398 
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MHC class I and II expression compared to control cells (Fig. 7A) as expected. 399 
However, when incubated with the proteasomal inhibitor, MG132, BDLF3 expressing 400 
cells showed no such reduction in surface MHC class I and MHC class II levels 401 
compared to control cells (Fig. 7B). Part abrogation of BDLF3 phenotype by MG132 402 
was observed after 4hr treatment, but the effect of MG132 treatment was maximal after 403 
16h (Supplementary Fig. 4). Similar results were seen when cells were treated with a 404 
second proteasomal inhibitor, bortezomib (Supplementary Fig. 5), whereas treatment 405 
with a lysosomal inhibitor, bafilomycin (Supplementary Fig. 6), did not prevent BDLF3 406 
induced downregulation of surface MHC molecules. These data indicate that BDLF3 407 
induced downregulation of surface MHC molecules is dependent upon the proteasomal 408 
pathway.   409 
As BDLF3 downregulates surface MHC molecules through increased internalization and 410 
delayed appearance (Fig. 6), we next examined what effect proteasomal inhibition might 411 
have on the kinetics of MHC class I and class II internalization and appearance at the 412 
cell surface of BDLF3 expressing cells. The results showed that MG132 completely 413 
abrogated the effect of BDLF3 on both the rate of internalization (Fig 7C) and the rate of 414 
appearance (Fig.7D), demonstrating an essential role of the proteasome in BDLF3 415 
induced MHC molecule downregulation.   416 
 417 
Given the essential role that the proteasome plays in BDLF3 induced reduction of 418 
surface MHC molecules, and that ubiquitination is an important component of the 419 
proteasomal pathway, we next assessed whether BDLF3 induces ubiquitination of 420 
22 
 
surface MHC molecules. To this end, MJS cells were transfected with various 421 
expression vectors including BDLF3, control vector and ubiquitin (Fig. 7E, F). These 422 
cells were then incubated with or without the proteasomal inhibitor, MG132. At 24h post-423 
transfection, surface MHC class I or MHC class II molecules were immunoprecipitated 424 
from BDLF3 expressing or control cells and resulting immunoblots were probed with 425 
ubiquitin-specific antibodies. As shown in Fig. 7, poly-ubiquitinated high molecular 426 
weight bands appeared in immunoblots for immunoprecipitated MHC class I (Fig. 7E) 427 
and MHC class II (Fig. 7F) in BDLF3 expressing cells treated with MG132. These 428 
ubiquitin-reactive bands were less pronounced both in control cells treated with MG132 429 
and in BDLF3-expressing cells not treated with MG132.   430 
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Discussion 431 
This study reveals the identity and mechanism of novel immune evasion gene, BDLF3, 432 
which induces downregulation of not only cell surface MHC class I but also MHC class 433 
II, to the extent that antigen recognition by both CD8+ and CD4+ virus-specific T cells is 434 
functionally impaired. The BDLF3 protein was first identified a number of years ago as 435 
the glycoprotein gp150, which is located at the cell membrane and in the virion, is not 436 
essential for EBV replication, and hitherto had no known function (18-20). Our study 437 
now allows a function to be assigned to the BDLF3 protein. 438 
The identification of BDLF3 as an immune evasion protein has an important impact on 439 
our knowledge of the T cell response to lytic EBV antigens and the protection of EBV 440 
infected cells from recognition by these T cells. EBV lytic cycle involves the 441 
synchronous expression of more than 60 viral proteins, many of which elicit strong CD4+ 442 
and CD8+ T cell responses, but various immune-evasion mechanisms enable EBV to 443 
persist as a lifelong infection. For CD8+ T cell responses to lytic cycle antigens, there is 444 
a pattern of immunodominance that correlates with the efficiency of antigen 445 
presentation during lytic cycle.  An earlier study by our group revealed that the known 446 
immune evasion genes, BGLF5, BNLF2a and BILF1 act in co-operation to afford 447 
protection to EBV infected cells against lytic specific CD8 T+ cell recognition. However, 448 
the ultimate protection that is seen in late phase lytic cycle could not be fully explained 449 
by the action of these known evasion genes (16). The identification of BDLF3, which is 450 
expressed during late stage lytic cycle, as a potent inhibitor of the MHC class I antigen 451 
presentation pathway makes it a prime candidate for the ‘missing link’ immune evasion 452 
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protein responsible for protecting EBV infected cells from CD8+ T cell responses during 453 
late stage lytic cycle.  454 
Another important feature of BDLF3 is its ability to induce MHC class II downregulation 455 
and evade CD4+ T cell recognition. Evidence is accumulating in the literature showing 456 
that viruses target multiple points on the MHC class II antigen presentation pathway, 457 
including: suppression of CIITA (28, 29), diversion or degradation of DR molecules 458 
during membrane transport (30) and direct targeting of the CD74 (invariant chain) 459 
chaperone of DR (8). Two viral genes expressed during EBV lytic cycle have been 460 
reported to manipulate MHC class II antigen presentation pathway. BZLF1 induces a 461 
marked downregulation of surface CD74 to impair antigen presentation and CD4+ T cell 462 
recognition (8), and Gp42 sterically inhibits interactions between TCR on the CD4+ T 463 
cell with MHC-II peptide complexes (10). The identification of BDLF3 as a novel MHC 464 
class II evasion gene from EBV indicates that, similarly to interference with MHC class I 465 
antigen presentation, interference with MHC class II antigen presentation very likely 466 
involves the cooperative action of multiple evasion genes.  467 
The fact that BDLF3 is an EBV late lytic cycle protein, suggests that it would help to 468 
provide enhanced protection of the virus-producing cells prior to release of mature 469 
virions. In addition, as BDLF3 can be detected in the EBV virion (31), this raises the 470 
possibility that BDLF3 can act immediately after new infections of B cells to modulate 471 
recognition by existing EBV specific CD4+ T cells. Considering the important role of 472 
MHC class II molecules and gp42 in EBV infection, and also the observation that 473 
BDLF3 knock out EBV virus particles can infect epithelial cells better than B cells (18), 474 
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we can propose a potential role of BDLF3 in the EBV infection. BDLF3 expression 475 
results in decreased MHC class II expression at the surface of lytically replicating cells, 476 
reducing the amount of MHC class II available to bind gp42. We would therefore predict 477 
that BDLF3 knockout virions may contain less envelope gp42 than wild type EBV, with a 478 
consequent enhanced ability to infect epithelial cells.  479 
Our data indicate that the mechanism of BDLF3 interference with the appearance of 480 
MHC molecules at, and internalization from, the cell surface, involves ubiquitination of 481 
MHC molecules and proteasome-dependent pathways. The targeting of MHC 482 
molecules for ubiquitination has been described for other viral immune evasion proteins, 483 
but the mechanism of action of BDLF3 is clearly distinct. An example is the K3 and K5 484 
proteins encoded by Kaposi’s sarcoma-associated herpesvirus (KSHV), which function 485 
as two membrane-bound E3 ubiquitin ligases and have been shown to facilitate the 486 
rapid endocytosis and subsequent degradation of MHC class I by inducing 487 
ubiquitination (32-37). Unlike K3 and K5, there is no evidence to show that BDLF3 itself 488 
is an E3 ubiquitin ligase, therefore it is very likely that BDLF3 functions via a different 489 
mechanism. Indeed in terms of the MHC class I downregulation, BDLF3 can affect all 490 
MHC class I alleles we studied, whereas K5 affects HLA-A and –B but has a weak 491 
effect on HLA-C, while K3 downregulates all HLA class I alleles (33). More importantly, 492 
KSHV K3 and K5 can downregulate a range of other surface proteins including B7-2, 493 
CD54 (ICAM-1), CD1d, CD31 (PECAM-1), IFN-γR1, MICA/B, BST-2, ALCAM, Syntaxin-494 
4 (38-42).  In contrast we found that BDLF3 targets MHC-I and MHC-II, but not CD54 495 
(Fig. 2) or MICA/B (data not shown). Another distinguishing feature of BDLF3 is that 496 
whilst the surface levels of MHC class I and class II were reduced by around 50%, there 497 
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was a minimal decrease of whole cell MHC class I and MHC class II (Fig. 5A, and 498 
Supplementary Fig. 3). That BDLF3 can induce a 50% reduction in surface MHC 499 
molecules against a reduction of less than 10% of the whole cell MHC molecules 500 
reflects the fact that there is relatively large reservoir of MHC class I and MHC class II 501 
inside the cells. Therefore, the 10% reduction in whole cell MHC class I and II could 502 
represent the complete degradation of the 50% of MHC class I and II that is lost from 503 
the surface in the presence of BDLF3. 504 
Whilst BDLF3 does not function as ubiquitin E3 ligase, it does nevertheless 505 
downregulate surface MHC class I and MHC class II through inducing ubiquitination. 506 
How might this be? One possible explanation is that it may recruit other cellular E3 507 
ubiquitin ligase proteins such as members of the membrane-associated RING-CH 508 
(MARCH) proteins, the cellular orthologues of K3 and K5. These proteins have been 509 
implicated in the regulation of cell surface molecules including MHC class I, MHC class 510 
II, ICAM and transferrin receptor (36, 43-46). Indeed, the overexpression of MARCH-IV 511 
and MARCH-IX proteins induces ubiquitination and rapid internalization of MHC class I 512 
(43). Numerous MARCH proteins have been identified that target MHC class I or MHC 513 
class II although, at the time of writing, no single known MARCH protein induces the 514 
ubiquitination of both MHC class I and class II without affecting other surface markers 515 
that are left unaffected by BDLF3 (47). Our preliminary experiments have not been able 516 
to demonstrate co-immunepreciptation of MHC molecules with BDLF3 (data not shown). 517 
Thus BDLF3 may recruit an as of yet unidentified MARCH family protein or perhaps 518 
several of these proteins. If so, then the specificity of BDLF3 would be due to the target 519 
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molecules of these recruited proteins. Future work will be aimed at resolving these 520 
possibilities. 521 
Considering the data that we have obtained for BDLF3, and the features that distinguish 522 
the effects of BDLF3 from previously characterized immune evasion proteins, we 523 
postulate that its mechanism of action is broadly as follows. As BDLF3 reduces the rate 524 
of appearance of MHC molecules at the cell surface to a greater extent than it increases 525 
the rate of endocytosis (Fig.6) we suppose that the reduced rate of appearance must be 526 
due at least in part to an effect on de novo synthesized MHC molecules trafficking to the 527 
surface. Therefore, BDLF3 targets for ubiquitination both de novo synthesized and 528 
recycling endocytosed MHC molecules. These ubiquitinated MHC molecules are 529 
directed for proteasomal degradation or, in the presence of proteasomal inhibitors, 530 
accumulate at the cell surface. The finer details of the biochemical mechanisms, and 531 
the identity of the ubiquitin ligases involved, remain to be resolved. 532 
The acquisition of immune evasion proteins has played a critical role in the evolution of 533 
viruses. It is interesting to note that an EBV homolog, the marmoset lymphocryptovirus 534 
(maLCV), which naturally infects new world nonhuman primates, lacks BDLF3. This 535 
may be relevant to the fact that serological studies reveal maLCV infection in 536 
marmosets to be much less ubiquitous than EBV in humans (48, 49). It might therefore 537 
be speculated that the acquisition of BDLF3 immune evasion functions is a later 538 
evolutionary event that contributes to the success of EBV in successfully colonizing the 539 
vast majority of the human population.  540 
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Figure legends 695 
Figure 1. Screening of EBV lytic genes to identify potential MHC class I immune 696 
evasion genes.  MJS cells were transiently transfected with pCDNA3.1-IRES-GFP 697 
plasmids encoding for a selection of EBV lytic genes. At 24h post transfection surface 698 
levels of MHC class I (A) and MHC class II (B) on GFP positive cells were analysed 699 
using two color flow cytometry. (C) AKBM cells were induced into lytic cycle by cross-700 
linking of B cell receptors for 1hr at 37ºC and analyzed at time points post-induction, as 701 
indicated, using western blot. Levels of BZLF1 protein (upper blot), BDLF3 protein 702 
(middle blot; stars indicate monomeric and trimeric BDLF3 protein) and, as a loading 703 
control, calregulin (lower blot) are shown.  704 
Figure 2. BDLF3 expression induces the down regulation of surface MHC class I 705 
and MHC class II. MJS cells (A-D) and DG75 cells (E-H) were transiently transfected 706 
with control-GFP or BDLF3-GFP plasmids. At 24h post transfection, two color flow 707 
cytometry was used to measure surface levels of MHC class I (A,E), MHC class II (B,F), 708 
TfR (C,G) and ICAM1 (D) or CD19 (H) in the GFP+ populations of control-GFP (solid 709 
line histogram), and BDLF3-GFP transfected cells (dashed line histogram). The grey 710 
histogram denotes background staining obtained with an isotype control antibody. 711 
Figure 3. BDLF3 induces downregulation of all HLA class I and class II alleles.  (A) 712 
The MHC class I negative cell line K562 transduced to stably express either HLA-A2, -713 
B35 or -Cw1 was electroporated with control-GFP or BDLF3-GFP plasmids. At 24h 714 
post-transfection, two color flow cytometry was used to measure surface MHC class I 715 
levels in the GFP+ populations in the control-GFP transfected (solid line histogram) and 716 
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the BDLF3-GFP transfected cells (dashed line). (B) HEK-293 cells stably expressing 717 
CIITA were transiently transfected with control-GFP or BDLF3-GFP plasmids. At 24h 718 
post-transfection, two color flow cytometry was used to measure surface HLA-DR and 719 
HLA-DQ levels in GFP+ populations in the control-GFP transfected (solid line histogram) 720 
and the BDLF3-GFP transfected cells (dashed line). The grey histogram denotes 721 
background staining obtained with an isotype control antibody.  722 
Figure 4. BDLF3 can inhibit EBV specific CD8+ and CD4+ T cell recognition. MJS 723 
cells were co-transfected with p509 plasmid (BZLF1 expression vector) together with 724 
control-GFP or BDLF3-GFP. At 24h post transfection, the MJS cells were co-cultured 725 
with effector T cells, BZLF1 (RAK)-specific CD8+ T cell clone, for a further 18hr and the 726 
supernatants were tested for the release of IFN-γ as a measure of T cell recognition. All 727 
results are expressed as IFN-γ release in pg/ml and error bars indicate standard 728 
deviation of triplicate cultures. (B) Total cell lysates were generated from the above 729 
transfections, and analyzed by western blotting using antibodies specific for BDLF3, 730 
BZLF1 or calregulin as a loading control. The asterisks adjacent to the BDLF3 blot 731 
indicate monomeric and trimeric BDLF3 protein. (C) MJS-DR51 cells were first 732 
transfected with EBNA1ΔNLS, allowed to recover in culture overnight, then were divided 733 
to two groups and transfected with either BDLF3-NGFR or Control-NGFR. After a 734 
further 24h, NGFR+/BDLF3+ or control NGFR+ cells were sorted with magnetic beads 735 
and used as targets for HLA-DR51 restricted EBNA1 (SNP) specific CD4+ T cell clones. 736 
Recognition was measured as pg/ml of IFN-γ release by T cell clones. Error bars 737 
represent standard deviation of the mean for triplicate assay replicates. Results are 738 
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representative of three independent experiments. (D) Total cell lysates were generated 739 
from the above transfections, and analyzed by western blotting using antibodies specific 740 
for BDLF3, EBNA1 or calregulin as a loading control. 741 
Figure 5. BDLF3 induces a more dramatic reduction in surface MHC class I and II 742 
compared to whole cell levels. (A) MJS cells were transiently transfected with control-743 
GFP or BDLF3-GFP plasmids. At 24h post transfection, two color flow cytometry was 744 
used to measure the level of surface MHC class I (upper left), MHC class II (middle left) 745 
and ICAM1 (lower left) in the viable GFP+  populations of control-GFP transfected (solid 746 
line histogram), and BDLF3-GFP transfected cells (dashed line histogram). The grey 747 
histogram denotes background staining obtained with an isotype control antibody. In 748 
parallel, these GFP+ transfected MJS cells were analysed for whole cell levels of MHC 749 
class I (upper right), MHC class II (middle right) and ICAM1 (lower right) using 750 
intracellular staining of fixed and permealized cells. The results are representative of 751 
repeated experiments. (B) Relative mean fluorescence intensity (MFI) of MHC class I, 752 
MHC class II and ICAM1 in BDLF3-GFP+ cells compared to control-GFP + cells were 753 
calculated. Results are the combined data from three independent experiments. White 754 
bars represent surface staining, grey bars represent whole cell staining. Differences that 755 
reached significance (p<0.05) in a Student’s Paired T test are denoted by an asterisk.  756 
Figure 6. BDLF3 induces more rapid internalization and delayed appearance of 757 
both MHC class I and class II at the cell surface. Internalization and appearance 758 
assays were performed on MJS cells transiently expressing control-GFP or BDLF3-759 
GFP. The GFP+ population was used to gate on BDLF3 expressing cells. Internalization 760 
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and appearance assays were performed on cells pre-treated on ice with saturating 761 
amounts of anti-MHC class I antibody or anti-MHC class II antibody. Cells were then 762 
washed and incubated at 37°C for up to 60 min. (A) For the internalization assay, viable 763 
cells harvested at each time point were stained with APC-conjugated goat anti-mouse 764 
IgG antibody, and analyzed using flow cytometry at the indicated times; this identifies 765 
the pre-labeled antibody-bound MHC molecules that remain at the surface while 766 
endocytosed labeled MHC molecules are not detected on the viable cells. The mean 767 
fluorescence intensities of staining were averaged for triplicate samples, and then 768 
normalized to the time 0 samples. (B) For the appearance assays, newly-arrived MHC-I 769 
and MHC-II molecules, which were not prelabeled with unconjugated antibodies, were 770 
detected by staining with APC-conjugated anti-MHC class I antibody or anti-MHC class 771 
II antibody. The mean fluorescence intensities of staining were averaged for triplicate 772 
samples, and then normalized to the time 0 samples. Results are representative of 773 
three independent experiments.  774 
Figure 7. Treatment of BDLF3 expressing cells with a proteasome inhibitor 775 
prevents down regulation of MHC class I and class II. MJS cells were transiently 776 
transfected with BDLF3-GFP or control-GFP plasmids, and then incubated in normal 777 
medium (A) or with MG132 (5µM) supplemented medium (B). At 24h post-transfection, 778 
two color flow cytometry was used to measure surface MHC class I (upper histograms), 779 
surface MHC class II (middle histograms) and surface ICAM1 (lower histograms) in 780 
GFP+  populations of control-GFP (solid line histogram), and BDLF3-GFP (dashed line 781 
histogram) transfected cells. The grey histogram denotes background staining obtained 782 
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with an isotype control antibody. Results are representative of repeated experiments 783 
(n>4). (C,D) MJS cells were transiently transfected with BDLF3-GFP or control-GFP 784 
plasmids, and then were incubated with MG132 (5µM). Following drug treatment, the 785 
rate of internalization (C) of MHC-I (top panel) and MHC-II (bottom panel), and the rate 786 
of appearance (D) of MHC-I (top panel) and MHC-II (bottom panel) were measured 787 
using the same method as in Fig. 6. (E, F) MJS cells were transfected with a ubiquitin 788 
expression plasmid plus either Control-NGFR or BDLF3-NGFR plasmids; these 789 
transfected cells were then divided in to two and incubated in normal medium or in 790 
medium supplemented with MG132. At 24h post transfection, NGFR+/BDLF3+ or control 791 
NGFR+ cells were sorted with magnetic beads, and surface MHC class I (C) or MHC 792 
class II (D) were immunoprecipitated, eluted, and then immunoblotted using anti-793 
ubiquitin antibody (P4D1). 794 







